Skip to content
value.today
Oragenics Inc. logo

Oragenics Inc.

Formerly Oragen, Inc.

Total raised
$35 M
5 rounds on record
Latest round
$13 M
Jul 2012
First round on record
Dec 2009
Today
Went public
See the company page

Oragenics Inc. is listed today as Oragenics, Inc.: market value, financials and filings are on its company page.

Funding rounds

5 counted as startup funding, 6 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Oragenics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2020$5 MPrivate placement after listing$2 to $10 million

Oragenics Inc.: Private sale, May 2020

Investors in this round

1 investor had bought by the notice of May 6, 2020: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Oragenics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Florida

People named in the notice

  • Alan Joslyn · Executive Officer, Director
  • Michael Sullivan · Executive Officer
  • Alan Dunton · Director
  • Charles Pope · Director
  • Frederick Telling · Director
  • Robert Koski · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On a merger: “The consideration for the acquisition consisted of (i) $1,925,000 (less payment of certain liabilities), (ii) 9,200,000 shares of common stock; (iii) warrants to purchase 9,200,000 shares of common stock; and (iv) potential contingent consideration.”

Signed by Michael Sullivan, Chief Financial Officer. Source: SEC Form D, newest notice filed May 6, 2020. Read the notice at the SEC.

equity, optionsSEC
Apr 2018$2 MPrivate placement after listingUnder $2 million

Oragenics Inc.: Private sale, Apr 2018

Investors in this round

2 investors had bought by the notice of Apr 12, 2018: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Oragenics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
$144,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Florida

People named in the notice

  • Alan Joslyn · Executive Officer, Director
  • Michael Sullivan · Executive Officer
  • Alan Dunton · Director
  • Charles Pope · Director
  • Frederick Telling · Director
  • Robert Koski · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • LADENBURG THALMANN & CO. INC. (CRD 505) · Miami, FloridaSold in NJ, NY

Remarks in the notice

  • On fees: “Sales commissions relates to commissions for the sale of common stock in the concurrent registered offering.”
  • On the amounts: “The total offering amount includes the concurrent registered offering of common stock.”

Signed by Michael Sullivan, Chief Financial Officer. Source: SEC Form D, newest notice filed Apr 12, 2018. Read the notice at the SEC.

equity, optionsSEC
Nov 2017$7 MPrivate placement after listing$2 to $10 million

Oragenics Inc.: Private sale, Nov 2017

Investors in this round

5 investors had bought by the notice of Nov 14, 2017: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Oragenics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$7 M of $7 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Florida

People named in the notice

  • Alan Joslyn · Executive Officer, Director
  • Michael Sullivan · Executive Officer
  • Alan Dunton · Director
  • Charles Pope · Director
  • Frederick Telling · Director
  • Robert Koski · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Michael Sullivan, Chief Financial Officer. Source: SEC Form D, newest notice filed Nov 14, 2017. Read the notice at the SEC.

equitySEC
May 2017$1 MPrivate placement after listingUnder $2 million

Oragenics Inc.: Private sale, May 2017

Investors in this round

3 investors had bought by the notice of May 19, 2017: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Oragenics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$1 M of $3 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Florida

People named in the notice

  • Alan Joslyn · Executive Officer, Director
  • Michael Sullivan · Executive Officer
  • Alan Dunton · Director
  • Charles Pope · Director
  • Frederick Telling · Director
  • Robert Koski · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Michael Sullivan, Chief Financial Officer. Source: SEC Form D, newest notice filed May 19, 2017. Read the notice at the SEC.

equitySEC
Jun 2016$5 MPrivate placement after listing$2 to $10 million

Oragenics Inc.: Private sale, Jun 2016

Investors in this round

3 investors had bought by the notice of Jul 13, 2016: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Oragenics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Florida

People named in the notice

  • Alan Joslyn · Executive Officer, Director
  • Michael Sullivan · Executive Officer
  • Alan Dunton · Director
  • Charles Pope · Director
  • Frederick Telling · Director
  • Robert Koski · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Michael Sullivan, Chief Financial Officer. Source: SEC Form D, newest notice filed Jul 13, 2016. Read the notice at the SEC.

equitySEC
Sep 2013$10 MPrivate placement after listing$2 to $10 million

Oragenics Inc.: Private sale, Sep 2013

Investors in this round

1 investor had bought by the notice of Oct 15, 2013: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Oragenics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
no minimum stated
What was sold
equity, debt
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
$5 million to $25 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Florida

People named in the notice

  • John Bonfiglio · Executive Officer, Director
  • Michael Sullivan · Executive Officer
  • Alan L. Dunton · Director
  • Charles L. Pope · Director
  • Christine Koski · Director
  • Frederick W. Telling · Director
  • Robert Koski · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The Company issued 1,300,000 shares to Intrexon Corporation in a private placement and 1,348,000 shares and note to Intrexon for a technology access fee in the amount of $1,956,000. Shares issued were based on a $3.00 per share price.”

Signed by Michael Sullivan, Chief financial officer and treasurer. Source: SEC Form D, newest notice filed Oct 15, 2013. Read the notice at the SEC.

equity, debtSEC
Jul 2012$13 MNo. 5$10 to $50 million

Oragenics Inc.: Raise no. 5, Jul 2012

Investors in this round

53 investors had bought by the notice of Aug 10, 2012: 53 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Oragenics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$13 M of $13 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
$899,698
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Florida

People named in the notice

  • John Bonfiglio · Executive Officer, Director
  • Michael Sullivan · Executive Officer
  • Alan L. Dunton · Director
  • Charles L. Pope · Director
  • Christine Koski · Director
  • Frederick W. Telling · Director
  • Robert Koski · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Griffin Securities, Inc. (CRD 43229) · New York, New YorkSold in CT, FL, GA, MA, MD, NC, NJ, NY, OH, PA, TX, VA, VT, WY

Remarks in the notice

  • On fees: “In addition to cash fees, the Placement Agent received warrants to acquire an aggregate of 771,169 shares of common stock.”

Signed by Michael Sullivan, Chief financial officer and treasurer. Source: SEC Form D and 1 amendment, newest notice filed Aug 10, 2012. Read the notice at the SEC.

equitySEC
Jun 2012$6 MNo. 4$2 to $10 million

Oragenics Inc.: Raise no. 4, Jun 2012

Investors in this round

1 investor had bought by the notice of Jun 15, 2012: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Oragenics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Florida

People named in the notice

  • John Bonfiglio · Executive Officer, Director
  • Michael Sullivan · Executive Officer
  • Alan L. Dunton · Director
  • Charles L. Pope · Director
  • Christine Koski · Director
  • Frederick W. Telling · Director
  • Robert Koski · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The Company issued 4,392,425 common shares to Intrexon Corporation pursuant to an Exclusive Channel Collaboration Agreement. No cash was received. The amount entered is based solely on the closing price of the Company's stock of $1.32 on 6/5/2012.”

Signed by Michael Sullivan, Chief financial officer and treasurer. Source: SEC Form D, newest notice filed Jun 15, 2012. Read the notice at the SEC.

equitySEC
Mar 2012$11 MNo. 3$10 to $50 million

Oragenics Inc.: Raise no. 3, Mar 2012

Investors in this round

1 investor had bought by the notice of Apr 5, 2012: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Oragenics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$11 M of $11 M offered
Smallest investment taken
no minimum stated
What was sold
equity, debt, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Florida

People named in the notice

  • John Bonfiglio · Executive Officer, Director
  • Michael Sullivan · Executive Officer
  • Alan L. Dunton · Director
  • Charles L. Pope · Director
  • Christine Koski · Director
  • Frederick W. Telling · Director
  • Robert Koski · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Company issued common stock and warrants in exchange for cancellation of $8,737,011 of indebtedness owed to the Koski Family Limited Partnership and a Note for up to $2.5 million in secured convertible debt.”

Signed by Michael Sullivan, Chief financial officer and treasurer. Source: SEC Form D, newest notice filed Apr 5, 2012. Read the notice at the SEC.

equity, debt, optionsSEC
Jul 2010$2 MNo. 2$2 to $10 million

Oragenics Inc.: Raise no. 2, Jul 2010

Investors in this round

1 investor had bought by the notice of Aug 11, 2010: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Oragenics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
$2,000,000
What was sold
equity, debt
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Florida

People named in the notice

  • Brian Brian Bohunicky · Executive Officer
  • David Brian Hirsch · Executive Officer, Director
  • Jeffrey Brian Hillman · Executive Officer, Director
  • Charles L. Pope · Director
  • Christine Brian Koski · Director
  • Frederick W. Telling · Director
  • Robert Brian Koski · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David Hirsch, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 11, 2010. Read the notice at the SEC.

equity, debtSEC
Dec 2009$3 MNo. 1$2 to $10 million

Oragenics Inc.: Raise no. 1, Dec 2009

Investors in this round

9 investors had bought by the notice of Jan 13, 2010: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Oragenics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Florida

People named in the notice

  • Brian Brian Bohunicky · Executive Officer
  • David Brian Hirsch · Executive Officer, Director
  • Jeffrey Brian Hillman · Executive Officer, Director
  • Christine Brian Koski · Director
  • Robert Brian Koski · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Excludes $1,000,000 in offering of common stock in exchange for $1,000,000 outstanding secured debt which was condition of transaction.”
  • On the use of proceeds: “While no proceeds were paid, we did issue shares to satisfy $54,062.50 owed to Chief Scientific Officer Jeff Hillman and $1.0M secured debt owed to the Koski FLP.”

Signed by David Hirsch, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 13, 2010. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Oragenics Inc. had no revenue when it filed its newest notice of a funding round (May 2020).

    SEC Form D (revenue range) · May 2020

  • Revenue range over time, as stated in its notices: revenue between $1 million and $5 million in 2016; no revenue in 2017; no revenue in 2018; no revenue in 2020.

    SEC Form D (revenue range) · May 2020

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · May 2020

Products and services#

No products or services of Oragenics Inc. are on record.

Investors#

1 named in official filings. Open an investor to see everything it has backed.

Investors in Oragenics Inc.
InvestorKindAmountRoundRoleSource
Odyssey Health, Inc.Companynot statednot statedHeld Series F preferred stock, 10% owner (Form 3, 2025)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 53 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Oragenics Inc.
NameRoleNamed in
Alan JoslynExecutive officerMay 2020
Michael SullivanExecutive officerMay 2020
John BonfiglioExecutive officerOct 2013
Brian Brian BohunickyExecutive officerAug 2010
David Brian HirschExecutive officerAug 2010
Jeffrey Brian HillmanExecutive officerAug 2010
Alan DuntonDirectorMay 2020
Alan JoslynDirectorMay 2020
Charles PopeDirectorMay 2020
Frederick TellingDirectorMay 2020
Robert KoskiDirectorMay 2020
Alan L. DuntonDirectorOct 2013
Charles L. PopeDirectorOct 2013
Christine KoskiDirectorOct 2013
Frederick W. TellingDirectorOct 2013
John BonfiglioDirectorOct 2013
Christine Brian KoskiDirectorAug 2010
David Brian HirschDirectorAug 2010
Jeffrey Brian HillmanDirectorAug 2010
Robert Brian KoskiDirectorAug 2010

Went public since 2012. Its SEC number is that of a company listed on a stock exchange.